// App-Quantinova.ai

11 : Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.

Researchers

Presenter

  • Claire Gallois

Principal Investigators

  • Jeffrey P. Meyers

  • Timothy Iveson

  • Steven R Alberts

  • Aimery De Gramont

  • Alberto F. Sobrero

  • Daniel G. Haller

  • Eiji Oki

  • Anthony Frank Shields

  • Caroline Kelly

  • Ioannis Boukovinas

  • Roberto Labianca

  • Frank A. Sinicrope

  • Ioannis Sougklakos

  • Takayuki Yoshino

  • Jeffrey A. Meyerhardt

  • Thierry Andre

  • Demetris Papamichail

  • Julien Taieb

Medical Centers

  • Hopital European Georges Pompidou, Paris, France

  • Mayo Clinic, Rochester, MN

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Franco-British Institute, Levallois-Perret, France

  • IRCCS Policlinico San Martino, Genova, Italy

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Cancer Research UK Glasgow Clinical Trials Unit, Glasgow, United Kingdom

  • Bioclinic Thessaloniki Medical Oncology Unit, Thessaloniki, Greece

  • Cancer Center, ASST Papa Giovanni XXIII, Bergamo, Italy

  • University of Heraklion, Heraklion, Greece

  • National Cancer Center, EPOC, Chiba, Japan

  • Dana-Farber Cancer Institute, Boston, MA

  • Sorbonne Université, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France

  • B.O. Cyprus Oncology Centre, Nicosia, Cyprus

  • Hopital European Georges Pompidou, Paris, France

Locations

  • France

  • United States

  • United Kingdom

  • Italy

  • Japan

  • Greece

  • Cyprus

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Oxaliplatin

  • Oxaliplatin, 5-fluorouracil and folic acid

  • Capecitabine + Oxaliplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved